<of treatment. The primary endpoint of the trial is response (measurable reduction in tumour
size) and the secondary endpoints are safety and quality of life. The trial is an open label
study and it is expected that information on the progress of the patients will become
available as recruitment progresses.>>
Progress of patients updated during the trial process. That could be good news for holders.